Raymond D. Meng - Concepedia

Author

Raymond D. Meng

Sarah Cannon

Also Known As

RAYMOND D. MENG, Raymond D Meng, Raymond D. Meng, Raymond Meng

Publications

Citations

H-Index

Concepts

All Affiliations

Sarah Cannon Tennessee Oncology Memorial Sloan Kettering Cancer Center Vall d'Hebron Hospital Universitari Yonsei University

About

Raymond D. Meng is an author at Sarah Cannon specializing in medicine, cancer therapeutics, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	580
2	Immunology	5	5	532
3	Allergy	1	1	240
4	Cell Biology	1	1	130
5	Pathology	1	1	62

Raymond D. Meng

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study Byoung Chul Cho, Delvys Rodríguez‐Abreu, Maen Hussein, The Lancet Oncology	2022	399
γ-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity Raymond D. Meng, Christopher C. Shelton, Yue-Ming Li, Cancer Research	2009	298
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). Delvys Rodríguez‐Abreu, Melissa L. Johnson, Maen Hussein, Journal of Clinical Oncology Pd-l1-selected NsclcImmunologyImmunoeditingPharmacotherapyImmunotherapeutics	2020	240
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors Cristina Saura, Desamparados Roda, Susana Roselló, Cancer Discovery	2016	167
p53-Independent Upregulation of KILLER/DR5 TRAIL Receptor Expression by Glucocorticoids and Interferon-γ Raymond D. Meng, Wafik S. El‐Deiry Experimental Cell Research Signal TransductionImmunologyImmune RegulationCell DeathReceptor (Biochemistry)	2001	130
The TRAIL Decoy Receptor TRUNDD (DcR2, TRAIL-R4) Is Induced by Adenovirus-p53 Overexpression and Can Delay TRAIL-, p53-, and KILLER/DR5-Dependent Colon Cancer Apoptosis Raymond D. Meng, E. Robert McDonald, M. Saeed Sheikh, Molecular Therapy	2000	114
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Nature	2024	102
A Randomized Controlled Trial of a Cardiopulmonary Resuscitation Video in Advance Care Planning for Progressive Pancreas and Hepatobiliary Cancer Patients Andrew S. Epstein, Angelo E. Volandes, Ling Y. Chen, Journal of Palliative Medicine	2013	92
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer Charles M. Rudin, Stephen V. Liu, Ross A. Soo, Journal of Clinical Oncology	2023	92
SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC). Charles M. Rudin, Stephen V. Liu, Shun Lü, Journal of Clinical Oncology Lba8507 BackgroundPrimary ResultsImmunologyImmunoeditingPharmacotherapy	2022	73

Page 1